JP2023505218A5 - - Google Patents
Info
- Publication number
- JP2023505218A5 JP2023505218A5 JP2022533414A JP2022533414A JP2023505218A5 JP 2023505218 A5 JP2023505218 A5 JP 2023505218A5 JP 2022533414 A JP2022533414 A JP 2022533414A JP 2022533414 A JP2022533414 A JP 2022533414A JP 2023505218 A5 JP2023505218 A5 JP 2023505218A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093006A JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944589P | 2019-12-06 | 2019-12-06 | |
| US62/944,589 | 2019-12-06 | ||
| US202063055085P | 2020-07-22 | 2020-07-22 | |
| US63/055,085 | 2020-07-22 | ||
| US202063057769P | 2020-07-28 | 2020-07-28 | |
| US63/057,769 | 2020-07-28 | ||
| PCT/US2020/063395 WO2021113701A1 (en) | 2019-12-06 | 2020-12-04 | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093006A Division JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505218A JP2023505218A (ja) | 2023-02-08 |
| JP2023505218A5 true JP2023505218A5 (https=) | 2023-12-08 |
| JP7693672B2 JP7693672B2 (ja) | 2025-06-17 |
Family
ID=74106148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533414A Active JP7693672B2 (ja) | 2019-12-06 | 2020-12-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| JP2025093006A Pending JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093006A Pending JP2025131696A (ja) | 2019-12-06 | 2025-06-04 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11919965B2 (https=) |
| EP (1) | EP4069373A1 (https=) |
| JP (2) | JP7693672B2 (https=) |
| KR (1) | KR20220110510A (https=) |
| CN (1) | CN114929343B (https=) |
| AU (1) | AU2020398167A1 (https=) |
| CA (1) | CA3160352A1 (https=) |
| IL (1) | IL293288A (https=) |
| MX (1) | MX2022006714A (https=) |
| WO (1) | WO2021113701A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023524875A (ja) | 2020-05-11 | 2023-06-13 | ヤンセン バイオテツク，インコーポレーテツド | 多発性骨髄腫を治療するための方法 |
| MX2024005392A (es) * | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117886939B (zh) * | 2023-12-15 | 2024-07-26 | 康众(广东)生物医药有限公司 | 一组抗bcma的纳米抗体及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025240287A1 (en) * | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
| WO2026059923A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| WO2026059917A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| LT3394103T (lt) * | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| IL313507A (en) * | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY199468A (en) * | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| MD3823665T2 (ro) * | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3132587A1 (en) * | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
-
2020
- 2020-12-04 CN CN202080090951.6A patent/CN114929343B/zh active Active
- 2020-12-04 AU AU2020398167A patent/AU2020398167A1/en active Pending
- 2020-12-04 CA CA3160352A patent/CA3160352A1/en active Pending
- 2020-12-04 WO PCT/US2020/063395 patent/WO2021113701A1/en not_active Ceased
- 2020-12-04 JP JP2022533414A patent/JP7693672B2/ja active Active
- 2020-12-04 KR KR1020227021340A patent/KR20220110510A/ko active Pending
- 2020-12-04 IL IL293288A patent/IL293288A/en unknown
- 2020-12-04 EP EP20834037.2A patent/EP4069373A1/en active Pending
- 2020-12-04 US US17/112,564 patent/US11919965B2/en active Active
- 2020-12-04 MX MX2022006714A patent/MX2022006714A/es unknown
-
2024
- 2024-02-01 US US18/429,887 patent/US20250051466A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093006A patent/JP2025131696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505218A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| FI3823664T3 (fi) | Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä | |
| KR101891845B1 (ko) | Cd3-특이적 결합 도메인에 의해 유발된 악영향의 예방 | |
| JP2020528768A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| JP2025131696A5 (https=) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| KR20160044042A (ko) | 부위-특이적 항체 접합 방법 및 조성물 | |
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JP7160533B2 (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| US12110337B2 (en) | Anti-CD27 antibodies and uses thereof | |
| JP2021528423A5 (https=) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023543152A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2024534602A5 (https=) | ||
| JP2023545183A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| JP2022517216A5 (https=) |